方盛制药：吲哚布芬片获得药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration certificate of Indobufene Tablets, indicating a significant advancement in its product pipeline [1] Group 1: Product Information - Indobufene Tablets are primarily used for ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The drug can also be used to prevent thrombosis during hemodialysis [1] Group 2: Financial Information - The cumulative research and development investment for this drug project amounts to approximately 28.72 million yuan (unaudited) [1]